Fibrinolysis Shutdown in COVID-19: Clinical Manifestations, Molecular Mechanisms, and Therapeutic Implications
Jonathan P. Meizoso, Hunter B. Moore, Ernest E. Moore
Abstract
The COVID-19 pandemic has introduced a global public health threat unparalleled in our history. The most severe cases are marked by ARDS attributed to microvascular thrombosis. Hypercoagulability, resulting in a profoundly prothrombotic state, is a distinct feature of COVID-19 and is accentuated by a high incidence of fibrinolysis shutdown. The aims of this review were to describe the manifestations of fibrinolysis shutdown in COVID-19 and its associated outcomes, review the molecular mechanisms of dysregulated fibrinolysis associated with COVID-19, and discuss potential implications and therapeutic targets for patients with severe COVID-19.
Topics & Concepts
FibrinolysisMedicineShutdownCoronavirus disease 2019 (COVID-19)ARDSPandemicIntensive care medicineSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakThrombosisVirologyPathologyInternal medicineDiseaseLungOutbreakInfectious disease (medical specialty)EngineeringNuclear engineeringCOVID-19 Clinical Research StudiesLong-Term Effects of COVID-19Dermatological and COVID-19 studies